Intercept Pharmaceuticals, Inc. — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/8d8ae36c-c5c4-4126-b65f-4764e49e41c5/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-68.2M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002693 |
| FY 2021 | $-100.4M | 2021-01-01 – 2021-12-31 | evidence 0001558370-23-002693 |
| FY 2020 | $-229.7M | 2020-01-01 – 2020-12-31 | evidence 0001558370-23-002693 |
| FY 2019 | $-312.4M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001314 |
| FY 2018 | $-285.5M | 2018-01-01 – 2018-12-31 | evidence 0001144204-19-011650 |
| FY 2017 | $-335.6M | 2017-01-01 – 2017-12-31 | evidence 0001144204-18-011793 |
| FY 2016 | $-402.5M | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-012180 |
| FY 2015 | $-229.2M | 2015-01-01 – 2015-12-31 | evidence 0001144204-17-012180 |
| FY 2014 | $-113.2M | 2014-01-01 – 2014-12-31 | evidence 0001144204-17-012180 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Intercept Pharmaceuticals, Inc. — all facts · Revenue · Net Income